C15 (Pentadecanoic Acid)
C15:0 (pentadecanoic acid) supplementation as Fatty15 has only two published human RCTs (Venn-Watson 2024 n=30 and Phang 2023 TANGO n=88), both industry-funded, both with null primary metabolic endpoints. A 2026 Mendelian randomization analysis (Steffen, n=7,085, NHLBI-funded) explicitly stated 'the collective evidence is not consistent with a causal cardiovascular benefit of C15:0.'
C15 (Pentadecanoic Acid) scored 5.6 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
C15 (pentadecanoic acid), also written as C15:0, is a 15-carbon odd-chain saturated fatty acid (OCFA) found in trace amounts in dairy fat at approximately 1% of total fatty acids. The supplement form is sold as Fatty15 by Seraphina Therapeutics under the proprietary ingredient name FA15, a free fatty acid produced via plant-based fermentation rather than animal extraction. Daily dose is 200 mg, delivered as two 100 mg vegan softgels with breakfast.
The discovery story behind C15 (pentadecanoic acid) is unusual. Veterinarian Stephanie Venn-Watson noticed that older Navy dolphins with higher circulating C15:0 had lower rates of metabolic syndrome and chronic inflammation. Her group filed a US Navy patent, founded Seraphina Therapeutics, and proposed in subsequent papers that C15:0 is the first essential fatty acid identified since omega-3 in 1929. That essentiality claim has not been endorsed by NASEM, EFSA, the AHA, the ADA, or any major independent nutrition body. A 2024 independent French review by Ciesielski (PMID 39395658) is titled 'controversial essentiality' and notes that classical deficiency studies are absent. The associated pathology, 'Cellular Fragility Syndrome,' is defined exclusively by Venn-Watson and lacks independent diagnostic criteria.
The proposed mechanism for C15 (pentadecanoic acid) includes partial PPAR-α/δ agonism, AMPK activation, mTOR suppression, mitochondrial complex II support, JAK-STAT inhibition, HDAC6 inhibition, and pentadecanoylcarnitine binding to 5-HT1A and histamine receptors. Every primary mechanistic claim originates from Venn-Watson's group and the BioMAP proprietary cell-platform assay (Eurofins), which is a phenotypic-similarity classifier rather than a direct receptor-binding study. No independent human-tissue replication of the PPAR / AMPK / HDAC6 profile has been published.
C15 (pentadecanoic acid) should be distinguished from C17:0 (heptadecanoic acid). A 2025 European Journal of Nutrition paper (DOI 10.1007/s00394-025-03841-4) jointly modeled both odd-chain fatty acids against metabolic syndrome and found that C15:0 became statistically non-significant once C17:0 entered the model; C17:0 carried the protective signal with OR 0.36, with 33.8% of the effect mediated through HOMA-IR. This is a direct challenge to the commercial premise of supplementing C15:0 in isolation. C15:0 is also synthesized endogenously from gut propionate; inulin supplementation alone raises serum C15:0 by approximately 13-17%, meaning the body produces meaningful quantities of C15:0 from soluble fiber without any pentadecanoic acid intake.
Terminology
- C15:0: Pentadecanoic acid, a 15-carbon odd-chain saturated fatty acid found in trace amounts in dairy fat (~1% of total fatty acids).
- OCFA: Odd-chain fatty acid. Saturated fatty acids with an odd number of carbons; historically a metabolic curiosity, now studied as biomarkers and putative bioactive lipids.
- C17:0: Heptadecanoic acid. The 17-carbon odd-chain saturated fatty acid that, in joint statistical models, carries the protective metabolic-syndrome signal previously attributed to C15:0.
- PPAR-α/δ: Peroxisome proliferator-activated receptors alpha and delta. Nuclear receptors regulating fatty acid oxidation and lipid metabolism. C15:0 is claimed to be a partial dual agonist.
- AMPK: AMP-activated protein kinase. Master cellular energy sensor; activation promotes fatty acid oxidation and glucose uptake.
- HDAC6: Histone deacetylase 6. A class IIb HDAC acting on cytoplasmic substrates including alpha-tubulin and HSP90.
- BioMAP: Eurofins proprietary phenotypic cell-platform assay that compares an intervention's profile to a database of known drugs. A similarity classifier, not a direct mechanistic test.
- Mendelian randomization (MR): Epidemiological method using genetic variants as proxies for an exposure to assess causality. A null MR result is strong evidence against a causal effect.
- GRAS: Generally Recognized As Safe. A US FDA designation. Self-affirmed GRAS means the manufacturer's expert panel made the determination, not the FDA.
- Cellular Fragility Syndrome (CFS): A condition coined by Venn-Watson defining low circulating C15:0 as a deficiency state. Not recognized by NASEM, EFSA, AHA, ADA, or any independent nutrition body.
- Pentadecanoylcarnitine (PDC): Carnitine ester of pentadecanoic acid, proposed as an endocannabinoid-like ligand of 5-HT1A and histamine receptors at micromolar concentrations.
- FAERS: FDA Adverse Event Reporting System. Public database of post-market adverse-event reports.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral (capsule, free fatty acid form) | Vegan softgel (Fatty15 brand) | 200 mg/day (single arm, both published RCTs) Both Venn-Watson 2024 (UC San Diego, n=30, 12wk) and Phang 2023 TANGO (n=88, 12wk) used 200 mg/day. | 100-400 mg/day Forum users occasionally report 400 mg/day to chase the post-hoc 5 µg/mL plasma threshold; no clinical evidence supports doubling. |
| Dietary (dairy fat) | Grass-fed butter, aged cheese, full-fat yogurt | Not formally dosed; Drouin-Chartier 2021 cohort meta linked higher dairy-fat biomarkers to ~12% lower CVD biomarker associations Captures C15:0 plus C17:0, butyrate, CLA, vitamin K2, and fat-soluble vitamins. | 3 tbsp grass-fed butter or 2 servings aged cheese daily Cost: $12-30/month for equivalent or greater nutritional payload. |
Protocols
Standard Fatty15 protocol Clinical
- Dose
- 200 mg/day
- Frequency
- Once daily with breakfast
- Duration
- Indefinite
Continuous use required; plasma C15:0 returns to baseline within ~6 weeks of cessation.
Dairy-first alternative Anecdotal + cohort
- Dose
- 1% C15:0 from grass-fed dairy
- Frequency
- Daily
- Duration
- Indefinite
Delivers broader nutritional spectrum at 5-10x lower cost than Fatty15 subscription.
How this score is calculated →
Upside (1.60 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 1.3 | 0.325 | |
| Breadth of Benefits | 15% | 1.5 | 0.225 | |
| Evidence Quality | 25% | 1.5 | 0.375 | |
| Speed of Onset | 10% | 2.0 | 0.200 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality Upside | 15% | 1.8 | 0.270 | |
| Total | 1.595 |
Upside Rationale
Efficacy (1.3/5.0): Across the only two published human RCTs of C15 (pentadecanoic acid), primary metabolic endpoints were null. Venn-Watson (UC San Diego, n=30, 12 weeks, 200 mg/day) successfully raised circulating C15:0 but produced no significant change in weight, BMI, lipid panel, fasting glucose, insulin, HOMA-IR, or hs-CRP. The Phang TANGO trial (n=88 Chinese women with NAFLD) reported a 30% liver-fat reduction driven by dietary intervention, with C15:0 supplementation only marginally additive (32% versus 22% with diet alone). Effect sizes for the C15:0-attributable component fall well below Cohen's d 0.2.
"The collective evidence is not consistent with a causal cardiovascular benefit of C15:0." Source: Steffen et al., Frontiers in Nutrition (Mendelian randomization, CARDIA + ARIC, n=7,085, NHLBI-funded)
Breadth of benefits (1.5/5.0): C15 (pentadecanoic acid) marketing claims systemic reach across cardiovascular, metabolic, hepatic, mitochondrial, immune, and cognitive systems, but human evidence remains confined to surrogate biomarker endpoints in two trials. The Venn-Watson trial measured 18 metabolic endpoints; only post-hoc subgroup signals (ALT -29 / AST -6 / Hgb +0.60 in the >5 µg/mL responder cluster) reached significance, and these were not pre-registered. Without independent replication of the BioMAP-derived multi-system mechanism in human tissue, breadth claims rest on phenotypic-similarity inference rather than measured cross-system effects. Two RCTs covering one organ system each does not support whole-body claims.
Evidence quality (1.5/5.0): C15 (pentadecanoic acid) sits at evidence tier 6-7 by BioHarmony's hierarchy. Only two published human RCTs exist (combined n=118), both industry-funded, both null on primary endpoints. Marketing materials reference 'seven RCTs' but five of those appear to be unpublished, secondary endpoints of the same two trials, or preclinical work. The European Journal of Nutrition joint C15:0/C17:0 analysis directly undermines the commercial premise by showing the protective metabolic signal lives at C17:0 (OR 0.36), not C15:0. The Steffen Mendelian randomization analysis is null for cardiovascular causality (p-values 0.19-0.73). A −1.0 Evidence Integrity Adjustment applies for industry-only origination plus commercial-premise-killer independent finding plus Mercola-authored 'independent' reviews polluting the literature.
Speed of onset (2.0/5.0): Plasma C15 (pentadecanoic acid) levels rise within 4-6 weeks of starting 200 mg/day per Venn-Watson pharmacokinetic data, but this measures circulating biomarker elevation rather than clinical benefit. Both published RCTs ran 12-week durations and failed to show meaningful biomarker change on primary metabolic endpoints in that timeframe. There is no published evidence of acute or short-term clinical effects from C15:0 supplementation. Users seeking subjective change within days or weeks have no reasonable basis to expect it. The intervention is not appropriate for any acute or subacute indication.
Durability (2.0/5.0): Plasma C15 (pentadecanoic acid) follows continuous-replenishment kinetics. Per Venn-Watson PK data the half-life of plasma C15:0 is approximately 14 days, returning to baseline within roughly 6 weeks of cessation. Even if benefits existed, they would not persist beyond the supplementation period. There is no published evidence of epigenetic, structural, or microbiome-mediated long-term changes from C15:0 supplementation. The intervention behaves as a maintenance therapy rather than a curative or transformative one. Compared to interventions producing durable shifts (resistance training, cardiometabolic conditioning, dietary pattern change), C15 (pentadecanoic acid) sits well below average on durability.
Bioindividuality upside (1.8/5.0): The post-hoc Venn-Watson responder analysis suggested users reaching plasma C15:0 above 5 µg/mL might experience ALT, AST, and hemoglobin shifts, but the threshold itself is post-hoc and the responder fraction is unreported. Endogenous synthesis from gut propionate (inulin raises serum C15:0 13-17% per Ciesielski review) means baseline circulating C15:0 varies meaningfully with fiber intake and microbiome composition, complicating any individual response prediction. Users at higher latitudes, on low-dairy or low-fiber diets, or with specific gut-microbiome profiles may theoretically respond differently, but no validated responder-prediction assay exists. The proprietary Cellular Fragility Test bundled at $239 has not been independently validated.
Downside (1.88 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 3.5 | 0.175 | |
| Time/Effort Burden | 5% | 1.2 | 0.060 | |
| Opportunity Cost | 5% | 3.8 | 0.190 | |
| Dependency / Withdrawal | 15% | 1.2 | 0.180 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.730 | |||
| Harm subtotal × 1.4 | 1.827 | |||
| Opportunity subtotal × 1.0 | 0.425 | |||
| Combined downside | 2.252 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.912 |
Downside Rationale
Safety risk (2.0/5.0): C15 (pentadecanoic acid) safety data extends only to 12 weeks of human supplementation across two small RCTs (combined n=118). C15:0 holds self-affirmed GRAS status from a Seraphina Therapeutics expert panel, not an FDA-initiated review. No FAERS adverse-event cluster, no FTC enforcement action, and no documented drug interactions have surfaced through current monitoring. However, a maternal-feeding mouse study reported insulin resistance signals in offspring fed pentadecanoic acid, contradicting the AMPK insulin-sensitizing narrative. This finding was not included in the GRAS dossier. A cross-sectional study in older Chinese adults found higher serum C15:0 correlated with approximately 2x increased mild cognitive impairment risk, raising a directional flag for the very demographic targeted by longevity marketing.
"Save your money." Source: CSPI Nutrition Action editorial on Fatty15. The Center for Science in the Public Interest characterizes the business model as "create a problem, market a test for the problem, then sell a solution."
Side effect profile (1.5/5.0): Both published C15 (pentadecanoic acid) RCTs reported no significant adverse events at 200 mg/day for 12 weeks, but the combined sample of 118 participants is far below the threshold needed to detect anything but the most common AEs. Forum signals from Reddit, Trustpilot, and Amazon reviews include occasional reports of LDL cholesterol elevations severe enough to prompt statin initiation, plus mild gastrointestinal complaints (nausea, fatty taste, oily stool) consistent with a free-fatty-acid softgel taken with breakfast. These are not formally characterized in the literature. No serious adverse events have been published. The score reflects the low intrinsic side-effect burden tempered by limited statistical power and inadequate long-term observation.
Financial cost (3.5/5.0): A Fatty15 subscription costs approximately $40 per month for 200 mg per day, or $239 for the first-month bundle that includes the proprietary Cellular Fragility Test. Equivalent C15:0 intake from grass-fed butter, aged cheese, or full-fat dairy costs $12-30 per month and includes C17:0, butyrate, conjugated linoleic acid, vitamin K2, and fat-soluble vitamins A and D, none of which are present in the isolated capsule. The 5-to-10x cost premium reflects intellectual-property protection on the proprietary plant-fermented FA15 ingredient and direct-to-consumer subscription margins, not superior bioavailability or efficacy data. No generic pentadecanoic acid supplement is currently available at scale through major retailers, so the monopoly price holds.
Time/effort burden (1.2/5.0): The mechanical effort of taking C15 (pentadecanoic acid) is trivial: two vegan softgels with breakfast, one bottle per month delivered by subscription. The effort dimension also captures cognitive load that mechanical-time minutes miss. A user must manage a recurring auto-ship subscription, decide whether to add the $239 Cellular Fragility Test bundle, and integrate a new capsule into a stack that may already include 8-15 daily pills (omega-3, vitamin D, magnesium, multivitamin, creatine, NAD precursor, others). Compared to whole-food C15:0 from grass-fed butter or aged cheese, which requires zero new cognitive load for users already eating dairy, supplementation adds modest decision and management overhead. The score of 1.2 reflects this as a near-floor effort burden, not zero.
Opportunity cost (3.8/5.0): Every dollar and stack slot allocated to C15 (pentadecanoic acid) is unavailable for higher-evidence interventions targeting the same outcomes. For metabolic and cardiovascular endpoints, omega-3 fatty acids (BioHarmony 6.8) carry substantially stronger RCT and meta-analytic support per dollar. For longevity-adjacent supplementation, vitamin D3 plus K2 (8.0), urolithin A (6.8), spermidine (7.0), and NMN or NR (6.8) each have superior independent replication and outcome-adjacent biomarker support. For liver health, dietary intervention alone produced 30% PDFF reduction in the Phang TANGO trial versus marginal C15:0 additivity. The opportunity cost is high because the dollar outlay is meaningful ($40-239/month), the alternatives are well-evidenced, and the subscription model promotes inertia.
Dependency / withdrawal (1.2/5.0): C15 (pentadecanoic acid) has no withdrawal pharmacology, no rebound, no neurotransmitter-receptor downregulation, and no HPA-axis adaptation. Plasma C15:0 follows continuous-replenishment kinetics with a half-life of approximately 14 days per Venn-Watson PK data, normalizing within 4-8 weeks of cessation per the same dataset. The only functional dependency is the requirement for continued daily intake to maintain plasma above the post-hoc 5 µg/mL responder threshold, but that threshold itself is post-hoc and may not predict any benefit. There is no addictive reward circuit involvement, no tolerance development, and no documented compulsive-use signal. Stopping at any time is unproblematic from a dependency standpoint, which is why this dimension scores at the 1.2 floor.
Reversibility (1.2/5.0): C15 (pentadecanoic acid) supplementation is fully reversible on biological timescales. Plasma C15:0 has a half-life of approximately 14 days and returns to pre-supplementation baseline within approximately 6 weeks of cessation per Venn-Watson PK modeling. No tissue accumulation has been reported, no methylation or other epigenetic changes have been documented, and no long-term residual effects have been characterized at 200 mg/day over 12 weeks. Compared to interventions producing semi-permanent biological shifts, such as HBOT-induced epigenetic clock changes, telomere lengthening protocols, or pre-conception interventions affecting oocyte quality, C15 (pentadecanoic acid) sits at the floor of the reversibility scale. A user who starts and later stops will be biologically indistinguishable from a never-user within roughly six weeks.
Verdict
"Is Fatty15 fool's gold?" Source: Dr. Michael Murray, ND. His comparative review places omega-3, berberine, and black seed oil ahead of Fatty15 on evidence-weighted return per dollar.
✅ Best for: C15 (pentadecanoic acid) supplementation has a narrow legitimate audience. Candidates include adults who do not consume dairy fat regularly, follow vegan or low-saturated-fat diets, and have specifically tested low circulating C15:0 below the proposed 0.2% total-fatty-acid threshold via the Cellular Fragility Test or equivalent lab. Researchers replicating Venn-Watson's PK data in independent cohorts may also rationally use the supplement. Users with documented NAFLD pursuing the Phang TANGO protocol may consider it as an adjunct to dietary intervention, with the understanding that diet does the heavy lifting. Anyone evaluating it should set a 12-week trial with pre and post lipid panels, ALT, AST, GGT, and a clear stop-decision based on objective change rather than subscription inertia.
❌ Avoid if: C15 (pentadecanoic acid) supplementation is not indicated for users who already consume grass-fed dairy fat (3 tablespoons of butter or 2 servings of aged cheese delivers comparable C15:0 plus C17:0, K2, butyrate, and CLA at one-fifth to one-tenth the cost). Avoid if budget for supplementation is limited and competing options (omega-3, vitamin D3+K2, urolithin A, NMN, spermidine) are unaddressed. Older adults pursuing longevity benefits should weigh the cross-sectional finding correlating higher serum C15:0 with approximately 2x increased mild cognitive impairment risk. Pregnant or nursing women should pause given the maternal-feeding insulin-resistance signal in mice. Users with known LDL hypercholesterolemia should approach cautiously given forum-reported LDL elevations, despite absence of formal published characterization.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ○ Metabolic Health Primary | 4.0 | Venn-Watson 2024 (Venn-Watson 2024, n=30, 12 weeks, 200 mg/day) was null on glucose, insulin, and HOMA-IR. The European Journal of Nutrition 2025 joint analysis of C15:0 and C17:0 found that once C17:0 entered the model, C15:0 lost statistical significance for metabolic syndrome and C17:0 carried the protective signal at OR 0.36, with 33.8% of the effect mediated through HOMA-IR. The result directly undermines the commercial premise of supplementing C15:0 in isolation. No insulin-resistance benefit has been demonstrated in any independent human trial. |
| ○ Liver / Detoxification Primary | 4.5 | The Phang 2023 TANGO trial (n=88 Chinese women with NAFLD, 12 weeks, Singapore) found dietary intervention drove a 30% PDFF reduction; C15:0 supplementation added only a marginal increment (32% versus 22% with diet alone). Venn-Watson 2024 reported a GGT decrease of 11 U/L in a post-hoc subgroup. Score reflects a possible weak adjunctive signal in NAFLD layered on top of dietary intervention; isolated C15:0 supplementation without dietary change has no replicated efficacy data on liver fat or transaminases. |
| ○ Cardiovascular Primary | 4.0 | Mendelian randomization analyses (Frontiers in Nutrition Mendelian randomization, NHLBI-funded, CARDIA + ARIC cohorts, n=7,085) explicitly stated 'the collective evidence is not consistent with a causal cardiovascular benefit of C15:0' with MR p-values for blood pressure, heart rate, and hypertension ranging 0.19-0.73. The Drouin-Chartier 2021 PLOS Medicine 18-cohort meta-analysis showed roughly 12% lower CVD biomarker association for higher dairy-fat biomarkers including C15:0, but that is a dairy-intake biomarker association, not a supplementation finding. Score lifts above floor only on observational signals from whole-food dairy. |
| ○ Longevity / Lifespan Primary | 3.5 | No human longevity outcome data exists. A 2024 cross-sectional study (citation pending) in older Chinese adults found higher serum C15:0 correlated with roughly 2x increased mild cognitive impairment risk, directly contradicting the longevity-marketing pitch aimed at this demographic. No clinical trial has measured biological-age clocks, telomere length, healthspan markers, or all-cause mortality in C15-supplemented subjects. Better-evidenced longevity bets at the same dollar outlay (omega-3, urolithin A, NMN, spermidine, vitamin D3 plus K2) all carry stronger evidence and lack the directional MCI signal. |
| ○ Anti-Inflammatory Primary | 4.0 | Venn-Watson 2024 was null on hs-CRP across the full 12-week 200 mg/day arm. Phang 2023 TANGO did not pre-specify systemic inflammatory markers as primary endpoints. The proposed JAK-STAT inhibition mechanism originates from BioMAP phenotypic-similarity data and has not been replicated in human tissue. There is no published evidence that 200 mg/day C15:0 supplementation lowers measured inflammatory cytokines, fibrinogen, white blood count, or other validated systemic inflammation markers. The score sits above floor only because the safety profile at 12 weeks is benign rather than pro-inflammatory. |
| ○ Blood Sugar / Glycemic Control | 4.0 | Venn-Watson 2024 was explicitly null on fasting glucose, fasting insulin, and HOMA-IR over 12 weeks at 200 mg/day in n=30. The European Journal of Nutrition 2025 joint analysis reported that 33.8% of the C17:0 metabolic-syndrome effect was mediated through HOMA-IR, a finding that survives controlling for C15:0 but does not transfer to it. The 2024 maternal mouse study (PMID 39434548) found pentadecanoic acid feeding raised offspring insulin resistance, contradicting the AMPK-sensitization narrative. Score sits at 4.0 reflecting the null efficacy plus directional preclinical concern. |
| ○ Cellular Senescence | 3.5 | The 'Cellular Fragility Syndrome' construct (Venn-Watson 2024) is defined exclusively by the patent-holding group and lacks independent diagnostic criteria. The proposed cellular-membrane-stability mechanism rests on BioMAP phenotypic similarity rather than direct senescence assays. No human trial has measured validated senescence biomarkers (p16INK4a, SASP cytokines, DNA damage markers, telomere shortening) in C15:0-supplemented subjects. Score is above the 1.0 floor only because membrane lipid composition can plausibly affect cellular function, while no direct senolytic or senomorphic data exist for C15:0 in humans. |
| ○ Energy / Fatigue | 3.5 | No subjective or objective energy endpoint reached significance in either published RCT (Venn-Watson 2024 or Phang 2023). The proposed mitochondrial-uncoupling and AMPK-activating mechanisms could plausibly affect cellular ATP production, but neither has been validated in human tissue. Forum reports of energy effects are not formally characterized and run the full range from null to mildly positive without placebo control. Score sits at 3.5 because the mechanism story is mid-strength while the human energy data is functionally absent at the 200 mg/day dose tested. |
| ○ Body Composition / Fat Loss | 3.5 | Venn-Watson 2024 reported no significant change in weight, BMI, or any body composition endpoint over 12 weeks at 200 mg/day. Phang 2023 TANGO reported PDFF reduction primarily driven by dietary intervention rather than C15:0 supplementation. There is no published trial measuring DEXA-quantified lean mass, fat mass, visceral adipose tissue, or waist circumference in C15:0-supplemented subjects. Score sits at 3.5 because of the null trial result rather than a clear directional signal; the supplement does not appear to drive body composition change in either direction at clinically relevant timescales. |
| ○ Skin / Beauty | 3.5 | No published trial has tested oral C15:0 supplementation against skin endpoints (wrinkle scoring, transepidermal water loss, sebum production, dermatology-validated quality scales). The proposed cell-membrane-stability mechanism is theoretically relevant to keratinocyte and dermal fibroblast lipid composition, but no human dermatology data exists. Venn-Watson 2024 did not measure skin endpoints. Score sits at 3.5 because the mechanism story is plausible while the data is absent; users seeking skin benefits have substantially better-evidenced options including topical retinoids, oral collagen peptides, and dietary omega-3. |
| ○ Fertility (Male) | 3.5 | No human fertility trial has tested C15:0 supplementation. The 2024 maternal-feeding mouse study (PMID 39434548) reported offspring insulin resistance after C15:0 exposure, raising a directional preclinical reproductive concern that has not been resolved in human data. PPAR-α agonists in general have a complex relationship with spermatogenesis (mechanistic concern but not consistent clinical signal). Score sits at 3.5 reflecting the absence of human data plus the preclinical reproductive flag; users planning conception should weigh this against the pregnancy-untested status of the supplement. |
| ○ Mitochondrial | 3.0 | Mitochondrial complex II rescue is a BioMAP-derived phenotypic-similarity claim (Venn-Watson group + Eurofins proprietary platform); no independent in-vivo replication in human tissue exists 14 years after the founding hypothesis. No published trial has measured ATP synthesis, mitochondrial respiration, mitochondrial DNA copy number, or other validated mitochondrial endpoints in C15:0-supplemented humans. The proposed pentadecanoylcarnitine (PDC) endocannabinoid mechanism for mitochondrial coupling rests on micromolar-affinity binding to 5-HT1A and histamine receptors, neither of which is a mitochondrial pathway. Score is below 4.0 because the mechanism story is single-source and unvalidated. |
| ○ Cognition / Focus | 3.0 | The 2024 cross-sectional study (citation pending) in older Chinese adults found higher serum C15:0 correlated with roughly 2x increased mild cognitive impairment risk, directly contradicting cognition-supportive marketing claims. No randomized trial has tested C15:0 supplementation against cognitive endpoints in any age group. CNS penetration of 200 mg/day oral C15:0 is uncharacterized; proposed PDC binding to 5-HT1A receptors is theoretical. Score sits at 3.0 because the only prospective directional signal is opposite the indication and there is no validated cognitive benefit to anchor against. |
| ○ Sleep Quality | 3.0 | No published trial has tested C15:0 supplementation against sleep endpoints (PSQI, Athens Insomnia Scale, polysomnography, actigraphy). Neither Venn-Watson 2024 nor Phang 2023 measured sleep variables. The proposed pentadecanoylcarnitine binding to 5-HT1A and histamine receptors is mechanistically adjacent to sleep regulation, but micromolar affinity is too weak to predict clinical sleep effects. Forum reports are mixed and uncontrolled. Score sits at 3.0 because there is no specific reason to expect a sleep effect at 200 mg/day and no data to confirm or refute one. |
| ○ Immune Function | 3.0 | JAK-STAT inhibition has been claimed from BioMAP phenotypic-similarity data, but no human immune-endpoint trial has tested C15:0. There is no published evidence that 200 mg/day C15:0 supplementation modulates measured immune cell counts, T cell or B cell function, antibody response to vaccination, or infection rates. Venn-Watson 2024 did not pre-specify immune endpoints. Score is mid-floor because the mechanism story is theoretical and the human immune outcome data is functionally absent. Score does not drop below 3.0 because there is no signal of immune harm at 12 weeks. |
| ○ Recovery / Repair | 3.0 | No published trial has tested C15:0 supplementation against athletic recovery, DOMS, training adaptation, or post-exercise inflammatory markers. Venn-Watson 2024 and Phang 2023 recruited general or NAFLD populations, not athletes. The proposed antioxidant and AMPK-activation mechanisms are mechanistically adjacent to exercise recovery but unvalidated for that endpoint. Score is mid-floor because the supplement is not actively contraindicated for athletes but offers nothing measured against established post-exercise antioxidants such as omega-3, tart cherry, or curcumin. |
| ○ HRV / Vagal Tone / Autonomic Balance | 3.0 | No published trial has measured heart rate variability, baroreflex sensitivity, or autonomic tone in C15:0-supplemented subjects. The Mendelian randomization analyses Mendelian randomization analysis included blood pressure and heart rate as endpoints with non-significant p-values (0.19-0.73), which is informative for autonomic function only by extension. The proposed PPAR-α/δ partial agonism could plausibly affect cardiac autonomic balance via fatty acid oxidation in cardiomyocytes, but this is mechanistic speculation. Score is mid-floor because there is no targeted HRV trial to anchor a higher or lower estimate. |
| ○ Hair / Nail Health | 3.0 | No published trial has tested C15:0 supplementation against hair growth, hair shedding, nail strength, or nail growth rate. The cellular-membrane-stability mechanism is theoretically applicable to follicle and nail-matrix cells, but this is speculative extrapolation rather than measured effect. Forum reports do not converge on a hair or nail signal. Score is at 3.0 because there is no specific reason to expect benefit at 200 mg/day oral and no data to anchor a higher or lower score; users seeking hair benefit have better-evidenced options including biotin (in deficient individuals), iron, and topical minoxidil. |
| ○ Geriatric / Aging Population | 3.0 | The 2024 cross-sectional study (citation pending) found higher serum C15:0 was correlated with roughly 2x increased mild cognitive impairment risk in older Chinese adults, the very demographic targeted by the longevity marketing. No randomized trial has tested C15:0 supplementation in adults over 65 years against any geriatric-specific endpoint (frailty, sarcopenia, falls, cognitive decline rate). Score is mid-floor because the only prospective directional signal in older adults runs opposite the marketed indication. |
Frequently Asked Questions
Does C15 (pentadecanoic acid) actually work?
C15 (pentadecanoic acid) supplementation has only two published human randomized controlled trials and both missed their primary metabolic endpoints. The Venn-Watson 2024 trial (UC San Diego, n=30, 12 weeks, 200 mg/day) raised circulating C15:0 levels but showed no significant effect on weight, BMI, lipids, glucose, insulin, or CRP. The Phang 2023 TANGO trial (n=88 Chinese women with NAFLD, 12 weeks) showed dietary intervention drove a 30% liver-fat reduction; C15:0 supplementation added only marginal benefit (32% versus 22% with diet alone). Marketing claims of 'seven RCTs' are not supported by the published literature.
Is C15 (pentadecanoic acid) safe long-term?
C15 (pentadecanoic acid) safety data extends only to 12 weeks of human supplementation across two small RCTs (Venn-Watson and Phang TANGO, combined n=118), which is insufficient to establish long-term safety. C15:0 holds self-affirmed GRAS status from a Seraphina Therapeutics expert panel, not an FDA-initiated review. No FAERS adverse-event cluster, no FTC enforcement action, and no documented drug interactions exist as of this scoring. However, a 2024 preclinical study reported maternal insulin resistance signals in mice fed pentadecanoic acid, contradicting the AMPK insulin-sensitizing narrative. Forum users occasionally report LDL cholesterol elevations requiring statin initiation. Theoretical interactions with PPAR-α agonists, anticoagulants, and glucose-lowering medications warrant caution despite absent clinical data.
How does C15 (pentadecanoic acid) work in the body?
The proposed mechanism of action for C15 (pentadecanoic acid) includes partial PPAR-α/δ agonism, AMPK activation, mTOR suppression, mitochondrial complex II support, JAK-STAT inhibition, HDAC6 inhibition, and pentadecanoylcarnitine endocannabinoid binding to 5-HT1A and histamine receptors. Every primary mechanistic claim originates from Venn-Watson's group or the BioMAP proprietary cell-platform assay (Eurofins), which is a phenotypic-similarity classifier rather than a direct receptor-binding study. No independent human-tissue replication of the PPAR / AMPK / HDAC6 profile exists. C15:0 is also synthesized endogenously from gut propionate, and inulin supplementation alone raises serum C15:0 by approximately 13-17 percent per Ciesielski 2024.
Is C15 (pentadecanoic acid) an essential fatty acid?
C15 (pentadecanoic acid) has not been recognized as an essential fatty acid by NASEM, EFSA, AHA, ADA, or any major independent nutrition body. The 'essential' label was coined by Venn-Watson and is propagated through Seraphina Therapeutics marketing. A 2024 independent French review by Ciesielski was titled 'controversial essentiality' and noted that classical deficiency studies are absent. The associated condition 'Cellular Fragility Syndrome' is defined exclusively by Venn-Watson; no independent diagnostic criteria exist. The body synthesizes C15:0 endogenously from gut propionate, and humans consume it through dairy fat at approximately 1 percent of total fatty acids, neither of which is consistent with classical essential-nutrient definitions.
Can I get C15 (pentadecanoic acid) from food instead of supplements?
C15 (pentadecanoic acid) occurs naturally in dairy fat at approximately 1 percent of total fatty acids, and three tablespoons of grass-fed butter or two servings of aged cheese deliver biologically meaningful quantities for $12-30 per month. Whole-food dairy also delivers C17:0 (which carries the actual metabolic-syndrome signal in joint analyses), conjugated linoleic acid, butyrate, vitamin K2, and fat-soluble vitamins A and D, none of which are present in the isolated Fatty15 capsule. Endogenous synthesis from gut propionate further contributes; soluble fiber such as inulin raises serum C15:0 by 13-17 percent per Ciesielski 2024. The dairy-and-fiber combination is approximately 5-10 times cheaper than a Fatty15 subscription with substantially broader nutritional payload.
Does C15 (pentadecanoic acid) reduce cardiovascular disease risk?
C15 (pentadecanoic acid) supplementation has not been shown to reduce cardiovascular disease risk in any prospective interventional trial. The most rigorous available test, the Steffen Mendelian randomization analysis (Frontiers in Nutrition, NHLBI-funded CARDIA and ARIC cohorts, n=7,085), concluded that 'the collective evidence is not consistent with a causal cardiovascular benefit of C15:0.' MR p-values ranged from 0.19 to 0.73, all non-significant. The Drouin-Chartier PLOS Medicine 18-cohort meta-analysis showed approximately 12 percent lower CVD biomarker associations for higher dairy-fat biomarkers, but this captured dairy intake, not C15 supplementation.
Why is C15 (pentadecanoic acid) so expensive compared to dairy fat?
C15 (pentadecanoic acid) as Fatty15 costs approximately $40 per month for a subscription delivering 200 mg per day, or $239 for the first-month bundle including the proprietary Cellular Fragility Test (Seraphina pricing page). Equivalent C15:0 intake from grass-fed butter, aged cheese, or full-fat dairy costs $12-30 per month and includes C17:0, butyrate, vitamin K2, and fat-soluble vitamins. The 5-to-10x cost premium reflects intellectual-property protection on the proprietary plant-fermented FA15 ingredient and direct-to-consumer marketing margins, not superior bioavailability or efficacy data per the CSPI Nutrition Action editorial. No generic pentadecanoic acid supplement is currently available at scale through major retailers.
Should I take C15 (pentadecanoic acid) for longevity?
C15 (pentadecanoic acid) is not currently supported by longevity outcome data in humans. A 2024 cross-sectional study (citation pending) in older Chinese adults found higher serum C15:0 was correlated with approximately 2x increased risk of mild cognitive impairment, directly contradicting the longevity marketing aimed at this demographic. No clinical trial has measured biological-age clocks, telomere length, healthspan markers, or all-cause mortality in C15-supplemented subjects. Better-evidenced longevity interventions for the same dollar outlay include omega-3 fatty acids, urolithin A, NMN or NR, spermidine, and vitamin D3 with K2, each of which has multiple human trials, biomarker improvements, or mortality-cohort signals that C15 currently lacks per the Bill Harris commentary on The Proof podcast.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions Changed | New Score | Tier |
|---|---|---|---|
| Independent RCT (non-Seraphina, n≥200) replicates AMPK / PPAR mechanism in human tissue | Evidence 1.5→3.0, Efficacy 1.3→2.5 | 6.4 / 10 | 👍 Worth trying |
| Long-term outcome trial (5+ yrs, n≥1,000) shows reduced all-cause mortality | Evidence 1.5→4.0, Efficacy 1.3→3.5, Breadth 1.5→3.5, Durability 2.0→3.5 | 7.4 / 10 | 💪 Strong recommend |
| FDA recognizes pentadecanoic acid as essential fatty acid via NASEM-equivalent process | Evidence 1.5→3.5, Bioindividuality 1.8→3.0 | 6.5 / 10 | 👍 Worth trying |
| Independent replication of the cognitive-impairment signal in second cohort | Safety 2.0→3.5, Side Effects 1.5→3.0, Bioindividuality 1.8→1.2 | 4.2 / 10 | ⚠️ Proceed with caution |
| Generic / commodity C15 supplement available at <$10/month with bioequivalence | Cost 3.5→1.5 | 6.0 / 10 | 👍 Worth trying |
Key Evidence Sources
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Emerging
The modern science on C15:0 is dominated by a single originator group. Venn-Watson et al. 2020 (Scientific Reports, PMID 32424181) proposed pentadecanoic acid as a potentially essential fatty acid based on cross-sectional associations between circulating C15:0 levels and lower cardiometabolic disease risk across 14,000-plus participants. A 2022 PLoS One study by the same group (PMID 35617322) compared C15:0 cell-based activities against omega-3 across twelve human cell-disease systems. A 2023 Nutrients paper (PMID 37960259, Venn-Watson and Schork) compared C15:0 to longevity compounds including rapamycin in BioMAP assays. No independent academic group has replicated the receptor-binding or clinical claims; both published human RCTs are industry-funded and missed their primary metabolic endpoints. Confidence is emerging given single-source origination and null primary endpoints.
Citations: pubmed.ncbi.nlm.nih.gov/32424181/, pubmed.ncbi.nlm.nih.gov/37960259/, pubmed.ncbi.nlm.nih.gov/35617322/
Other interventions for Metabolic Health
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.600 − 1.880 = -0.280
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((-0.280 + 7) / 12) × 10 = 5.6 / 10
